The myelodysplastic syndromes.
作者信息
Layton D M, Mufti G J
机构信息
Department of Haematology, King's College School of Medicine and Dentistry, London.
出版信息
Br Med J (Clin Res Ed). 1987 Jul 25;295(6592):227-8. doi: 10.1136/bmj.295.6592.227.
Abstract
摘要
相似文献
1
The myelodysplastic syndromes.骨髓增生异常综合征
Br Med J (Clin Res Ed). 1987 Jul 25;295(6592):227-8. doi: 10.1136/bmj.295.6592.227.
2
Initial transfusion frequency and survival in myelodysplastic syndromes: hopping onto a fast train to nowhere.
Leuk Lymphoma. 2014 Oct;55(10):2221-2. doi: 10.3109/10428194.2014.891027. Epub 2014 Feb 24.
3
Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndromes.
Eur J Haematol. 2015 Jun;94(6):463. doi: 10.1111/ejh.12521. Epub 2015 Mar 16.
4
Prognostic factors in myelodysplastic syndromes.骨髓增生异常综合征的预后因素。
Hematol Oncol. 1993;11 Suppl 1:20-6.
5
6
Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment.原发性骨髓增生异常综合征的生存趋势：按诊断和治疗年份对1000例患者的比较分析
Blood Cancer J. 2016 Apr 8;6(4):e414. doi: 10.1038/bcj.2016.23.
7
Survival outcomes in iron chelated and non-chelated patients with lower-risk myelodysplastic syndromes: Review and pooled analysis of observational studies.低危骨髓增生异常综合征患者接受铁螯合治疗与未接受螯合治疗的生存结局：观察性研究的综述与汇总分析
Leuk Res. 2017 Jun;57:104-108. doi: 10.1016/j.leukres.2017.03.007. Epub 2017 Mar 18.
8
[Treatment of myelodysplastic syndromes aside from clinical studies].[除临床研究外的骨髓增生异常综合征的治疗]
Dtsch Med Wochenschr. 1995 Nov 3;120(44):1527.
9
Incidence and outcomes of paediatric myelodysplastic syndrome in the United States.美国儿童骨髓增生异常综合征的发病率及转归
Br J Haematol. 2018 Mar;180(6):898-901. doi: 10.1111/bjh.14460. Epub 2017 Feb 27.
10
Myelodysplastic syndromes.骨髓增生异常综合征。
Annu Rev Med. 2010;61:345-58. doi: 10.1146/annurev.med.051308.132852.
本文引用的文献
1
Platelet function in preleukaemia.
Scand J Haematol. 1981 Jan;26(1):65-71. doi: 10.1111/j.1600-0609.1981.tb01626.x.
2
Proposals for the classification of the myelodysplastic syndromes.骨髓增生异常综合征的分类建议。
Br J Haematol. 1982 Jun;51(2):189-99.
3
Effect of chemotherapy for the dysmyelopoietic syndrome.化疗对骨髓生成异常综合征的影响。
Cancer Treat Rep. 1981 Jul-Aug;65(7-8):601-5.
4
5
Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid.维甲酸诱导人早幼粒细胞白血病细胞系（HL-60）分化
Proc Natl Acad Sci U S A. 1980 May;77(5):2936-40. doi: 10.1073/pnas.77.5.2936.
6
Induction of differentiation of human myeloid leukemia cells by inhibitors of DNA synthesis.
Exp Hematol. 1982 Oct;10(9):774-81.
7
Natural killer (NK)-cell activity and antibody-dependent cellular cytotoxicity (ADCC) in primary preleukemic syndrome.原发性白血病前期综合征中的自然杀伤（NK）细胞活性和抗体依赖性细胞毒性（ADCC）
Leuk Res. 1984;8(2):239-47. doi: 10.1016/0145-2126(84)90147-4.
8
Serous effusions in monocytic leukaemias.单核细胞白血病中的浆液性积液。
Br J Haematol. 1984 Nov;58(3):547-52. doi: 10.1111/j.1365-2141.1984.tb04002.x.
9
Skin infiltration associated with chronic myelomonocytic leukaemia.
Br J Haematol. 1983 Feb;53(2):257-64. doi: 10.1111/j.1365-2141.1983.tb02019.x.
10
Allogeneic marrow transplantation in the treatment of preleukemia.异基因骨髓移植治疗白血病前期
Ann Intern Med. 1984 May;100(5):689-93. doi: 10.7326/0003-4819-100-5-689.
Zotero 插件